购物车
- 全部删除
- 您的购物车当前为空
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) 是人源化靶向 CD22 的 IgG4 抗体。Inotuzumab 是 Inotuzumab ozogamicin 的裸抗,可用于合成抗体-活性分子偶联物 (Inotuzumab ozogamicin)。Inotuzumab 可于研究急性淋巴细胞白血病和非霍奇金淋巴瘤。
为众多的药物研发团队赋能,
让新药发现更简单!
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) 是人源化靶向 CD22 的 IgG4 抗体。Inotuzumab 是 Inotuzumab ozogamicin 的裸抗,可用于合成抗体-活性分子偶联物 (Inotuzumab ozogamicin)。Inotuzumab 可于研究急性淋巴细胞白血病和非霍奇金淋巴瘤。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 2,320 | 现货 | |
5 mg | ¥ 6,470 | 现货 | |
10 mg | ¥ 8,720 | 现货 | |
25 mg | ¥ 12,900 | 现货 | |
50 mg | ¥ 17,300 | 现货 |
产品描述 | Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4 antibody targeting CD22. Inotuzumab is a naked antibody to Inotuzumab ozogamicin and can be used to synthesize antibody-active molecule conjugators (Inotuzumab ozogamicin). Inotuzumab can be used to study acute lymphoblastic leukemia and non-Hodgkin's lymphoma. |
别名 | 英妥珠单抗 |
分子量 | Approximately 146.48 kDa. |
CAS No. | 1660159-36-3 |
存储 | store at low temperature | store at -80°C | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.